Background: Human papillomavirus (HPV) infection is the main cause of invasive cervical cancer, but cofactors may act in conjunction with HPV. We performed a pooled analysis of seven case-control studies to examine the effect of one possible HPV cofactor, herpes simplex virus-2 (HSV-2) infection, in the etiology of invasive cervical cancer. Methods: Blood and exfoliated cervical specimens were obtained from 1263 case patients with invasive cervical cancer (1158 with squamous-cell carcinomas and 105 with adeno-or adenosquamous-cell carcinomas) and 1117 age-matched control subjects. Western blot analysis and/or an enzyme-linked immunosorbent assay were used to detect type-specific serum antibodies to HSV-2 and HSV-1, and Chlamydia trachomatis serum antibodies were detected using a micro-immunofluorescence assay. HPV DNA was detected using a polymerase chain reaction assay. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were computed from unconditional logistic regression models. Results: Overall, HSV-2 seropositivity was higher among case patients with squamouscell carcinoma (44.4%, 95% CI = 41.5% to 47.3%) or adenoor adenosquamous-cell carcinoma (43.8%, 95% CI = 34.2% to 53.5%) than among control subjects (25.6%, 95% CI = 23.0% to 28.2%). Cervical specimens from 1098 (94.8%) squamous-cell carcinoma case patients, 95 (90.5%) adeno-or adenosquamous carcinoma case patients, and 164 (14.7%) control subjects were positive for HPV DNA. Among the HPV DNA-positive women, HSV-2 seropositivity was associated with increased risks of squamous-cell carcinoma (OR = 2.19, 95% CI = 1.41 to 3.40) and adeno-or adenosquamous-cell carcinoma (OR = 3.37, 95% CI = 1.47 to 7.74) after adjustment for potential confounders. A similar association between HSV-2 seropositivity and squamous-cell carcinoma risk was observed after further controlling for markers of sexual behavior (OR = 1.96, 95% CI = 1.24 to 3.09). Among control subjects, HSV-2 seropositivity was associated with markers of sexual behavior, but not with cervical HPV DNA positivity. 
Human papillomavirus (HPV) infection is the main etiologic factor for invasive and pre-invasive cervical neoplasia (1) . Recent studies suggest that HPV infection is necessary for the development of invasive cervical cancer (2) . Cofactors that act in conjunction with HPV, however, may also be important for the development of cervical neoplasia or invasive cervical cancer. Potential HPV cofactors include smoking, multiparity, long duration of oral contraceptive use (3) , and other sexually transmitted infections.
Herpes simplex virus type 2 (HSV-2) infection was first considered as a possible causal agent for cervical cancer in the 1960s and 1970s (4, 5) . Inactivated HSV-2 was shown to transform cells in vitro (6) . After HPV DNA was detected in cervical cancer tissue, it was hypothesized that HSV-2 infections might initiate mutations and carcinogenesis in HPV-infected cervical cells (7) . The role of HSV-2 in the development of cervical cancer was questioned, however, when HSV-2 DNA was not consistently found in cervical cancer biopsy specimens (8) , leading some to propose that HSV-2 acts as a "hit-and-run" agent (9) to cause intracellular changes that do not require the retention of HSV viral genes. Subsequently, molecular evidence from in vitro laboratory data renewed interest in the possible synergism between HPV and HSV-2 infections in the etiology of cervical cancer (10, 11) . Specifically, in vitro data suggest that the XhoII subfragment of the HSV-2 genome induces the malignant transformation of HPV-immortalized cervical cells and may be retained in cervical cancer tissue (12) .
Five case-control studies have examined the role of HSV-2 infection in the etiology of invasive cervical cancer by using highly sensitive polymerase chain reaction (PCR)-based assays to detect cervical HPV DNA (13) (14) (15) (16) (17) . One of those studies (13) found a statistically significant association between invasive cer-vical cancer and HSV-2 seropositivity, after controlling for the presence of HPV DNA, for study subjects from the study site in Spain, but not for those from Colombia (13) . When subjects from both locations were tested for the presence of specific subclasses of HSV-2 immunoglobulin G (IgG) antibodies, higher antibody titers of IgG1 were associated with an increased risk of invasive cervical cancer among study subjects in Spain, but not among study subjects in Colombia (14) . Two other studies conducted in China (15) and in Honduras (16) that controlled for the presence of specific HPV DNA types found that HSV-2 was not a statistically significant risk factor for invasive cervical cancer. One common limitation of all of these studies, however, is that they used relatively nonspecific serologic assays to distinguish between HSV-2 antibodies (which are almost exclusively associated with genital infections) and HSV-1 antibodies (which are primarily associated with nongenital infections) (18) . Although a study from Thailand (17) showed a statistically significant association between invasive cervical cancer and typespecific HSV-2 antibodies after controlling for the presence of HPV DNA detected by PCR, analyses that were restricted to HPV DNA-positive participants were not presented.
To examine the influence of HSV-2 infection as a cofactor of HPV infection in the etiology of invasive cervical cancer, we performed a pooled analysis of seven case-control studies of invasive cervical cancer that were conducted in Thailand, the Philippines, Morocco, Peru, Brazil, Colombia, and Spain (19) (20) (21) (22) (23) (24) using extensive questionnaire data, type-specific HSV-2 serologic testing, and PCR-based assays that detected a wide range HPV viral types.
SUBJECTS AND METHODS

Contributing Studies and Data and Blood Collection
The studies that contributed to this pooled analysis were conducted in seven countries that had different incidences of invasive cervical cancer. Regions covered by these studies include high-incidence populations in Africa [i.e., Morocco (23) (22) ], and a low-incidence population in Spain (19) . All studies used similar protocols and questionnaires for subject recruitment and data collection.
The methods that were used and HPV findings that were obtained for each study have already been described (19) (20) (21) (22) (23) (24) . In brief, case patients were eligible for these studies if they had incident, histologically confirmed invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous-cell carcinoma of the cervix and lived in predefined study areas or were attending the reference hospitals. Case patients had not received previous treatment for cervical carcinoma. Skilled pathologists reviewed the histology slides of the cases of carcinoma and confirmed the diagnoses. Clinical cancer stage was defined according to the International Federation of Gynecology and Obstetrics (25) .
Control subjects were population-based for the studies conducted in Spain and Colombia and hospital-based for the studies conducted at the other sites, and all control subjects were frequency-matched to case patients by quinquennium of age. For the hospital-based studies, women were not eligible to participate as control subjects if they had any condition that was related to risk factors for cervical cancer (e.g., neoplasias of the reproductive tract or tobacco-related diseases [i.e., lung cancer or cardiovascular or cerebrovascular diseases]). Only case patients and control subjects for whom HSV-2 serology and HPV DNA laboratory results were available were included in this analysis. Thus, the numbers of case patients and control subjects from each of the seven studies that were included in our study differ from those reported in the original publications. Of the case patients included in our study, 1158 had squamous-cell carcinoma of the cervix and 105 had invasive adeno-or adenosquamous-cell carcinoma of the cervix; 1117 control participants were included.
Personal interviews of study participants were conducted by trained interviewers with the use of a standardized questionnaire that included questions about sociodemographic factors, smoking habits, sexual and reproductive history, history of Pap smear screening, and reported history of sexually transmitted infections.
Women who participated in the seven studies were asked to provide 10 mL of blood for the detection of serum antibodies to HSV-2, HSV-1, and Chlamydia trachomatis. Blood samples were processed by centrifugation at the site of collection. The separated serum was aliquotted, frozen at -20°C, and shipped to Lyon, France, for storage.
Women who agreed to participate in our study provided written informed consent. All protocols were approved by the Institutional Review Boards of Brazil, Colombia, Morocco, Peru, the Philippines, Spain, Thailand, and the IARC in accordance with the revised Helsinki Declaration of 1983.
HPV DNA Detection
Cervical exfoliated cells were collected from all subjects, processed, and stored as described in the original studies (19) (20) (21) (22) (23) (24) . Cervical biopsy specimens were also obtained from case patients and were kept frozen at -70°C. Cervical exfoliated cells from control subjects and cervical exfoliated cells or biopsy specimens from case subjects were shipped to central laboratories in Baltimore or Amsterdam, where the HPV DNA testing was performed as detailed below.
Detailed descriptions of the PCR-based hybridization assays, the reference gold standard, that were used to detect HPV DNA are provided in the individual publications of the various studies (19) (20) (21) (22) (23) (24) . Briefly, HPV DNA detection and typing were performed using PCR-based methods to amplify a small fragment of the HPV L1 gene. All PCR assays were performed by laboratory personnel who were blinded to the case or control status of the subjects from whom the samples were obtained. DNA quality was evaluated by amplifying the ␤-globin gene from the same samples by using ␤-globin gene-specific oligonucleotide primers. For samples from the studies conducted in Colombia and Spain, MY09/MY11 consensus (i.e., broad spectrum) primers were initially used to amplify HPV DNA in the analyses conducted in the central laboratory in Baltimore (19) ; for samples from the Brazilian study, GP5/6/TS primers (20) were initially used to amplify HPV DNA in the analyses conducted in the central laboratory in Amsterdam. For samples from the remaining studies, GP5+/6+ primers were used to amplify HPV DNA in analyses conducted in the central laboratory in Amsterdam (20) (21) (22) (23) . Ultimately, GP5+/6+ primers (26) were used to test all specimens that were labeled as 'unknown' with respect to HPV type on the basis of results obtained by first using the MY09/MY11 or the GP5/6/TS. PCR products were assessed for HPV DNA positivity by low-stringency Southern blot hybrid-ization using HPV type-specific DNA probes (27) . For those samples that were positive for HPV DNA by hybridization, the genotype of the HPV species was determined by Southern blot hybridization using oligonucleotide probes that were specific for 37 different HPV types (HPV 6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45 , 66, and 68) to reamplify specimens from all case patients who were both positive for ␤-globin amplification and classified as either HPV X or HPV DNA-negative as well as specimens from a sample of control subjects who were ␤-globin-positive and HPV DNA-negative as previously described (2).
HSV-2 IgG Antibody Detection
Serologic testing for the presence of antibodies to HSV-2 was performed at the University of Washington (Seattle) by individuals who were blinded to case or control status of subjects who provided the blood samples. The University of Washington Virology Laboratory (Seattle, WA) HSV western blot analysis, the reference gold standard (28, 29) , was used to detect typespecific HSV-2 and HSV-1 antibodies in sera obtained from subjects who lived in Thailand, Morocco, Peru, Colombia, and Spain. To improve the specificity of previously presented findings (13), updated type-specific HSV-2 serology results from the retesting of sera from the Spain and Colombia study with the western blot are included in this article.
Sera collected from subjects who lived in Brazil and the Philippines were screened for HSV-2 IgG antibodies by using the Gull/Pre-Meridian HSV-2 enzyme-linked immunosorbent assay (ELISA; Gull Laboratories, Salt Lake City, UT), according to the manufacturer's instructions. All sera with positive, equivocal, or borderline negative ELISA results were retested with the western blot assay to obtain HSV-2 type-specific results (30).
C. trachomatis Antibody Detection
Type-specific serum IgG antibodies to C. trachomatis were detected with the use of a micro-immunofluorescence assay that used purified elementary bodies of C. trachomatis serovar A and pooled serovars BDE, CJHI, and FGK (31) . Purified elementary bodies of Chlamydia pneumoniae and Chlamydia psittaci were included in the antigen panel to determine whether the sera contained cross-reactive antibodies to those organisms.
Statistical Analysis
Unconditional logistic regression models were fitted to individual data, and the association between HSV-2 seropositivity and invasive cervical cancer was assessed with likelihood ratio tests (32) . To examine the association between HSV-2 and squamous-cell invasive cervical cancer, we first performed separate analyses for each study center. The data from all centers were then pooled for a combined analysis. We present only the results from the pooled analysis for the association between HSV-2 seropositivity and adeno-or adenosquamous-cell carcinomas because of the limited number of case patients that had these diagnoses. Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were computed from the unconditional logistic regression models, which included, as indicated, terms for age (in 5-year categories), study center, history of Pap smear screening (ever versus never), oral contraceptive use (never, <5 years of use, ജ5 years of use), number of full-term pregnancies (0, 1-2, 3-4, ജ5), C. trachomatis seropositivity (seronegative versus seropositive), the number of lifetime sexual partners (ഛ1, 2, ജ3), and age at first sexual intercourse (younger than 17 years, 17-20 years, 21 years or older). Subjects with missing values were excluded from statistical analyses. HPV DNA positivity was considered as a categorical variable by HPV type (HPV-negative; HPV type 16; high-risk HPV types other than HPV 16; HPV types other than high-risk HPV types, including low-risk HPV types or HPV X) and was included in models that were adjusted for HPV positivity or were restricted to HPV-positive women. Because only a few women used injectable contraceptives, women who reported previous hormonal contraceptive use were all considered to be oral contraceptive users (3) .
Tests for linear trends of ORs were performed by assigning an increasing score for each level of the categorized variable and fitting the scores in the model as a continuous variable. To test for heterogeneity among the study centers, the difference between the log likelihood of the model that considered the interaction between centers and the exposure of interest and the log likelihood of the model that included the main effects only was compared to the chi-square distribution with degrees of freedom equal to the number of centers minus one. All P values reported are from two-sided tests. Table 1 shows the seroprevalence of HSV-2 and HSV-1 antibodies and the prevalence of cervical HPV DNA for 1158 case patients with squamous-cell invasive cervical cancer, 105 case patients with adeno-or adenosquamous invasive cervical cancer, and 1117 control subjects, by study center and overall. Overall, HSV-2 seroprevalence was statistically significantly higher (P<.001) among the case patients with squamous-cell invasive cervical cancer (44.4%, 95% CI ‫ס‬ 41.5% to 47.3%) or adenoor adenosquamous invasive cervical cancer (43.8%, 95% CI ‫ס‬ 34.2% to 53.5%) than it was among the control subjects (25.6%, 95% CI ‫ס‬ 23.0% to 28.2%). HSV-2 seropositivity among control subjects differed substantially by country, ranging from 9.2% (95% CI ‫ס‬ 6.2% to 12.1%) in the Philippines to 56.9% (95% CI ‫ס‬ 44.6% to 68.3%) in Colombia. HSV-1 prevalence was similar for case patients with squamous-cell invasive cervical cancer (80.3%, 95% CI ‫ס‬ 77.9% to 83.3%), case patients with adeno-or adenosquamous invasive cervical cancer (85.7%, 95% CI ‫ס‬ 73.6% to 95.2%), and control subjects (89.6%, 95% CI ‫ס‬ 87.0% to 92.1%). A total of 1098 (94.8%, 95% CI ‫ס‬ 93.5% to 96.1%) case patients with squamous-cell invasive cervical cancer, 95 (90.5%, 95% CI ‫ס‬ 84.8% to 96.2%) case patients with adeno-or adenosquamous invasive cervical cancer, and 164 (14.7%, 95% CI ‫ס‬ 12.6% to 16.8%) control subjects were HPV DNA-positive. As expected, the prevalence of DNA from high-risk HPV types was higher among case patients with squamous-cell invasive cervical cancer (89.3%, 95% CI ‫ס‬ 87.5% to 91.1%) and adeno-or adenosquamous invasive cervical cancer (87.9%, 95% CI ‫ס‬ 81.2% to 94.0%) than it was among control subjects (9.8%, 95% CI ‫ס‬ 8.1% to 11.6%) (data not shown). Median age was similar among the HPV DNApositive case patients with squamous-cell carcinoma, the HPV DNA-positive case patients with either adeno-or adenosquamous invasive cervical cancer, and the control subjects (49 years, 48 years, and 47 years, respectively) ( Table 1) .
RESULTS
HSV-2 seropositivity among the control subjects was statistically significantly associated with markers of sexual behavior (Table 2 ). In the multivariable analysis, HSV-2 seropositivity was statistically significantly associated with cohabiting (OR ‫ס‬ 2.23, 95% CI ‫ס‬ 1.28 to 3.87); with being single, separated, divorced, or widowed (OR ‫ס‬ 1.56, 95% CI ‫ס‬ 1.06 to 2.31); and with having had three or more lifetime sexual partners (OR ‫ס‬ 2.9, 95% CI ‫ס‬ 1.67 to 5.02). HSV-2 seropositivity was also higher among women who had used oral contraceptives for 5 years or longer or who were seropositive for C. trachomatis. HSV-2 seropositivity was not statistically significantly associated with age, educational attainment, smoking habits, number of full-term pregnancies, age at first intercourse, condom use, or HPV DNA type. Overall, HPV DNA positivity was not associated with HSV-2 seropositivity among control participants (OR ‫ס‬ 0.91, 95% CI ‫ס‬ 0.59 to 1.40). Similarly, HSV-2 seropositivity was not associated with HPV DNA positivity among control participants (OR ‫ס‬ 0.98, 95% CI ‫ס‬ 0.71 to 1.48 [data not shown]). Fig. 1 shows the ORs for invasive cervical cancer among HPV DNA-positive case patients and control subjects, according to HSV-2 seropositivity. An increased risk of squamous-cell invasive cervical cancer was observed for HSV-2-positive participants from all study centers; however, the increased risk was statistically significant only for participants from study centers in the Philippines (OR ‫ס‬ 9.64, 95% CI ‫ס‬ 1.24 to 74.74) and Peru (OR ‫ס‬ 3.71, 95% CI ‫ס‬ 1.39 to 9.92). Among the HPV DNA-positive participants, the pooled OR for squamous-cell invasive cervical cancer was 2.19 (95% CI ‫ס‬ 1.41 to 3.40) and that for adeno-or adenosquamous invasive cervical cancer was 3.37 (95% CI ‫ס‬ 1.47 to 7.74). There was no statistically significant heterogeneity between study centers for either squamous-cell (P ‫ס‬ .24) or adeno-or adenosquamous (P ‫ס‬ .43) invasive cervical cancer. Among the women who were positive for DNA from high-risk HPV types, HSV-2 seropositivity was also associated with increased risks of squamous-cell invasive cervical cancer (adjusted OR ‫ס‬ 2.6, 95% CI ‫ס‬ 1.5 to 4.3) and adeno-or adenosquamous invasive cervical cancer (adjusted OR ‫ס‬ 4.2, 95% CI ‫ס‬ 1.7 to 10.1) (data not shown). Among women who were infected with HPV 16, HSV-2 seropositivity was associated with elevated risks for squamous-cell invasive cervical cancer (adjusted OR ‫ס‬ 4.0, 95% CI ‫ס‬ 1.8 to 9.1) and adeno-or adenosquamous invasive cervical cancer (adjusted OR ‫ס‬ 6.7, 95% CI ‫ס‬ 1.6 to 29.2) (data not shown). The presence of HSV-1 serum antibodies was not associated with an increased risk of squamous-cell invasive cervical cancer among HPV DNA-positive participants (OR ‫ס‬ 1.4, 95% CI ‫ס‬ 0.6 to 3.0) (data not shown). Table 3 shows the combined effects of HSV-2 seropositivity and selected characteristics associated with sexual behavior and oral contraceptive use on the risk of squamous-cell invasive cervical cancer among HPV DNA-positive women. In the mul- tivariable model that adjusted for a woman's number of sexual partners and her age at first intercourse in addition to the factors listed in Fig. 1 , the association between HSV-2 seropositivity and squamous-cell invasive cervical cancer was slightly reduced (OR ‫ס‬ 1.96, 95% CI ‫ס‬ 1.24 to 3.09) when compared with results obtained from the model that did not adjust for number of sexual partners and age at first intercourse (Fig. 1 ). Having had two or more lifetime sexual partners (OR ‫ס‬ 1.13, 95% CI ‫ס‬ 0.72 to 1.78) was not statistically significantly associated with an increased risk of squamous-cell invasive cervical cancer after adjustment for HSV-2 seropositivity. By contrast, there was a statistically significant association between squamous-cell carcinoma and a younger age at first intercourse (OR for first intercourse before the age of 17 years versus first intercourse at 21 years or older ‫ס‬ 2.61, 95% CI ‫ס‬ 1.47 to 4.63).
We conducted additional analyses to examine the effect of Among the 1048 HPV DNA-positive case patients with squamous-cell invasive cervical cancer for which the clinical stage of invasive cervical cancer was known, the OR for those with stage I and/or II cancers (adjusted OR ‫ס‬ 2.5, 95% CI ‫ס‬ 1.5 to 4.1) was similar to the OR for those with stage III and/or IV cancers (adjusted OR ‫ס‬ 2.4, 95% CI ‫ס‬ 1.4 to 4.0) (data not shown). The association between HSV-2 serum antibodies and squamous-cell invasive cervical carcinoma in HPV DNA-positive women did not change after adjustment for the presence of either single or multiple HPV infections (OR for all squamous-cell invasive cervical cancer ‫ס‬ 2.19, 95% CI ‫ס‬ 1.41 to 3.40) (data not shown). Results of analyses restricted to HPV DNA-positive women that did not control for HPV type were similar to those presented in Fig. 1 : the OR for squamous-cell cancer was 2.0 (95% CI ‫ס‬ 1.3 to 3.0), and the OR for adeno-or adenosquamous-cell cancer was 2.6 (95% CI ‫ס‬ 1.3 to 5.3) (data not shown).
We also examined the effect of HSV-2 seropositivity on the risk of invasive cervical cancer among all case patients and control subjects after adjusting for HPV DNA positivity and other confounders (Fig. 2) . The results of those analyses were similar to the results presented in Fig. 1 for the HPV DNApositive women. HSV-2 seropositivity was associated with statistically significant increased risks of squamous-cell invasive cervical cancer (OR ‫ס‬ 1.72, 95% CI ‫ס‬ 1.21 to 2.44) and adenoor adenosquamous invasive cervical cancer (OR ‫ס‬ 2.43, 95% CI ‫ס‬ 1.22 to 4.81); there was no statistically significant heterogeneity between study centers for either squamous-cell (P ‫ס‬ .51) or adeno-or adenosquamous (P ‫ס‬ .57) invasive cervical cancer (Fig. 2 ). In the model that further adjusted for the number of sexual partners and age at first intercourse, the association between HSV-2 seropositivity and squamous-cell invasive cervical cancer remained statistically significant (OR ‫ס‬ 1.9, 95% CI ‫ס‬ 1.2 to 3.1) with no statistically significant heterogeneity between study centers (P ‫ס‬ .16) (data not shown). In the model that adjusted for all other confounders except HPV DNA positivity, the OR for HSV-2 seropositivity and squamous-cell invasive cervical cancer was 1.9 (95% CI ‫ס‬ 1.2 to 3.1) (data not shown).
To examine whether the associations between HSV-2 and invasive cervical cancer were due to residual confounding by the sexual behavior of a woman's male partner, we investigated the effect of HSV-2 seropositivity after further controlling for her male partner's reported number of lifetime sexual partners, in addition to the factors adjusted for in Figs. 1 and 2 , in the five studies that interviewed the male partners of the study partici- pants (33) ; the association between HSV-2 and squamous-cell invasive cervical cancer was similar before and after adjustment for the male partner's number of lifetime sexual partners (data not shown).
DISCUSSION
Our analysis contributes to the understanding of the role of HSV-2 infection in the etiology of invasive cervical cancer because it was restricted to women who were positive for HPV DNA as ascertained by PCR-based techniques and for whom type-specific HSV-2 serology results were obtained. Results from this pooled analysis suggest that genital HSV-2 infection may act in conjunction with HPV infection to modestly increase the risk of invasive cervical cancer. The association between the presence of HSV-2 antibodies in serum and invasive cervical cancer was consistent for both squamous-cell and adeno-or adenosquamous carcinomas.
The initial epidemiologic evidence that suggested that HSV-2 infection is a potential etiologic factor for invasive cervical cancer was based on data that compared HSV-2 seropositivity among cases patients and control subjects that did not adequately take into account HPV infection (34) . Three casecontrol studies of invasive cervical cancer that did control for the presence of HPV serum antibodies reported ORs of 2.2 (95% CI ‫ס‬ 1.1 to 4.5) (35), 1.4 (95% CI ‫ס‬ 0.81 to 2.4) (36), and 1.2 (95% CI ‫ס‬ 0.8 to 1.8) (37) . However, because those ORs were adjusted for HPV seropositivity, residual confounding from HPV infection may be expected in those studies. Indeed, a proportion of the women who are HPV DNA-positive, including approximately 50% of those with invasive cervical cancer (38) , might have no detectable HPV antibodies in their serum. Although a large case-control study of invasive cervical cancer in Latin America reported an OR of 1.5 (95% CI ‫ס‬ 1.2 to 1.9) for those who were HSV-2 seropositive, HPV infection in that study was detected using an in situ hybridization assay that is less accurate than the PCR-based assay used in our study (39) . A nested case-control study found no association between HSV-2 seropositivity and invasive cervical cancer in 27 patients with invasive cervical cancer and 45 patients with carcinoma in situ after controlling for HPV-16 serum antibodies (OR ‫ס‬ 0.6, 95% CI ‫ס‬ 0.2 to 1.4) (40). The western blot reference standard for HSV-2 antibody detection was used in only one of these studies (37) , thus limiting the ability of these studies to specifically distinguish between HSV-2 and HSV-1 antibody responses.
Our results confirm those of another study (41) that showed that HSV-2 seropositivity is a reliable marker of past sexual behavior. It is thus difficult to determine from previous studies whether HSV-2 is a true etiologic factor or whether the associa- Table 3 . Odds ratios (ORs) of squamous-cell carcinoma of the cervix and corresponding 95% confidence intervals (CIs) among HPV DNA-positive women, according to the combined effects of herpes simplex virus type 2 (HSV-2) seropositivity, sexual behavior markers, and oral contraceptive use* tion between HSV-2 serum antibodies and invasive cervical cancer is due to a residual effect of HPV infection or other sexually transmitted infections. In our pooled analysis of invasive cervical cancer, the association between HSV-2 seropositivity and invasive cervical cancer was not substantially reduced when we additionally adjusted for a woman's reported number of lifetime sexual partners and her age at first sexual intercourse. Conversely, our results indicate that a woman's reported number of lifetime sexual partners is not an independent risk factor for invasive cervical cancer after allowance for HPV and HSV-2 infections. The effect of HSV-2 was consistent in strata of number of lifetime sexual partners and C. trachomatis infection (42), providing further evidence that the effect of HSV-2 may not represent exposure to other sexually transmitted infections. Thus, the effect of HSV-2 ascertained here is unlikely to represent either a surrogate marker of HPV infection or a woman's sexual behavior. Type-specific HSV-1 antibodies, which primarily represent a woman's past exposure to nongenital infections, were, unlike HSV-2 antibodies, not associated with an increased risk of squamous-cell invasive cervical cancer in our study. Although we found no statistically significant heterogeneity between study centers, it is worth noting that HSV-2 seropositivity was more strongly associated with an increased risk of invasive cervical cancer in countries where HSV-2 seroprevalence was below 10% among women in the control group (i.e., Spain and the Philippines) than in countries where HSV-2 seroprevalence was greater than 40% among women in the control group (i.e., Colombia and Brazil).
HSV-2, like HPV, can infect cervical squamous epithelial tissue in the squamocolumnar junction, where invasive cervical cancer arises. It has been estimated that concomitant herpetic cervicitis is present in 70%-90% of first-episode HSV-2 infections and in 12%-20% of recurrent external genital lesions (43) . Ulcerative herpetic lesions may serve as HPV cofactors by facilitating the access of HPV to the basal cell layer. Alternatively, inflammatory responses induced by herpetic infections may interfere with a woman's ability to mount an effective immune response to HPV infection by suppressing a woman's T helper cell-mediated immune response (44), or they may increase the risk of cervical carcinogens by inducing the production of nitric oxide that may result in cellular DNA damage in HPV-infected cells (45) . HSV-2 infection may also increase the risk that an oncogenic HPV infection will progress to cervical neoplasia, possibly by increasing HPV replication or the integration of HPV DNA sequences in infected host cells (46) . Although HSV DNA or proteins have not been consistently detected in cervical tumors (47) , it is possible that HSV may act on host cellular DNA by a hit-and-run mechanism. Further in vitro studies are required to examine whether HSV-2 infection increases HPV viral load or whether HSV-2 infection is capable of transforming human cervical cells that are infected by high-risk HPV types.
Our study has several strengths. It is the largest study to investigate the association between HSV-2 infection and invasive cervical cancer and one of the few to ascertain a broad range of HPV types and to incorporate type-specific serologic testing to detect previous HSV-2 infection. To our knowledge, only one other study (17) used type-specific HSV-2 serologic testing and PCR to detect HPV DNA; however, that study did not show separate results for HPV DNA-positive participants as did our study.
This study also has several potential limitations. First, the use of hospital-based control subjects at five of the study sites may have led to biased results if HSV-2 seroprevalence among those control subjects was not representative of the prevalence among the population source of the invasive cervical cancer case patients. Control participants from those five study sites, however, had a wide range of diagnoses and were ascertained in large, tertiary public hospitals that had wide reference populations (20) (21) (22) (23) (24) , thus reducing the possibility of any substantial selection bias. All invasive cervical cancer case patients in our study were also newly diagnosed and had not been treated previously for invasive cervical cancer, and the frequency of HSV-2 seropositivity among the case patients did not vary by the clinical Fig. 2 . Odds ratios (ORs) of invasive carcinoma of the cervix and corresponding 95% confidence intervals (CIs) among all case patients and control subjects according to herpes simplex virus type 2 (HSV-2) seropositivity (HSV-2 + ). The referent group was HSV-2-seronegative women (HSV-2 -); ORs were adjusted for age, study center, HPV DNA type (negative, HPV 16, high-risk HPV types other than HPV 16, and other HPV types), history of Pap smear, oral contraceptive use, number of full-term pregnancies, and Chlamydia trachomatis seropositivity. The center of each square corresponds to the estimated OR, and the area of the square is inversely proportional to the variance of the logarithm of the OR and is hence an indication of the amount of statistical information in each estimate. The horizontal line through the square indicates the 95% CI. Diamonds plot the summary ORs for all squamouscell invasive cervical cancer or adeno-or adenosquamous invasive cervical cancer data together. The center of each diamond represents the OR, and the left and right extremes of each diamond show the 95% CIs. The solid vertical line represents the OR of 1, indicating no effect, and the dashed vertical line represents the pooled OR for all squamous-cell invasive cervical carcinomas.
stage of invasive cervical cancer. A second potential limitation is that human immunodeficiency virus (HIV) antibodies were not evaluated in our study. However, the prevalence of HIV among middle-aged women (median ages between 43 and 56 years) in the study years in the participating countries was expected to be very low (48) .
Our decision to analyze HPV DNA-positive participants separately, albeit justified by the causal link between HPV infection and the development of invasive cervical cancer (2), did not alter the relationship between HSV-2 seropositivity and invasive cervical cancer risk. HSV-2 seropositivity was not associated with HPV DNA-positivity among control participants, and the association between HSV-2 and invasive cervical cancer among all study participants was consistent with that among HPV-positive women.
Any interpretation of our study findings must consider issues related to the detection of cervical HPV infection in study participants. Persistent HPV infections have been shown to increase the risk of the progression of an HPV infection to cervical dysplasia (49) . Because there is currently no reliable marker of persistent HPV infection, case-control studies have the limitation that one cross-sectional measurement of HPV infection cannot distinguish between transient and persistent infections. To increase the likelihood of examining an effect of HSV-2 infection among persistent HPV carriers, some analyses have been limited to women who are all HPV DNA-positive for high-risk HPV types, which are more likely to represent persistent infections than are nononcogenic HPV types (50) . The association between HSV-2 seropositivity and risk of squamous-cell carcinoma among women who were HPV DNA-positive for high-risk types was similar to that among HPV DNA-positive women. HPV DNA detection, however, has a different meaning among case patients and control subjects. Among case patients, HPV DNA positivity should indicate a persistent HPV infection, whereas some control subjects may have a transient HPV infection or have been previously infected with HPV in the past and have cleared their infection. Given that the ascertainment of overall HPV prevalence and the relative distribution of HPV types may be differential by case or control status, we controlled for HPV positivity in stratified categories by HPV type (HPV 16, high-risk HPV types other than HPV 16, or other HPV types).
In conclusion, the results of our pooled analysis suggest that although HSV-2 infection may act in conjunction with HPV infection to increase the risk of invasive cervical cancer, the effect of HSV-2 infection on invasive cervical cancer risk is modest compared with the strong effect of HPV infection on invasive cervical cancer risk. Future studies are needed to elucidate at which step in the pathogenesis of HPV-induced cervical carcinogenesis HSV-2 infection may be relevant.
